Umehara H, Kumagai S, Kashii S, Nagaoka K, Hoshino T, Imura H
Second Department of Internal Medicine, Kyoto University.
Ryumachi. 1990 Oct;30(5):369-73, 374; discussion 373-4.
A case of Reiter's syndrome with severe keratoderma being successfully treated with oral Etretinate is reported. A 38 year-old man was referred to our hospital in December, 1985 for treatment of refractory skin eruptions and polyarthralgia. He previously experienced urethritis in December, 1983 with subsequent development of high fever, balanitis, skin eruptions and polyarthritis. Treatments with antibiotics, anti-inflammatory drugs and glucocorticoids were ineffective at that time. The patient was diagnosed as Reiter's syndrome based on his clinical symptoms and the presence of HLA-B27. He was treated in our clinic with oral administration of Etretinate, aromatic retinoids, at the initial doses of 40 mg/day with subsequent increase up to 75 mg/day in 2 weeks. This maintenance dose was continued for two months, resulted in improvements of joint pain, skin eruptions and the laboratory abnormalities. The doses of Etretinate was gradually decreased and then was discontinued after 4 months, when approximately 90% of the skin lesion disappeared. No noticeable side-effect was observed except slight stomatitis. The remission continued for about 2 and half years after cessation of Etretinate without any medication. However, evidence of relapse with the same skin lesions and arthralgia was observed in March, 1989. A repeated treatment with oral Etretinate was attempted with similar but slightly delayed effects.
报告了1例用口服依曲替酯成功治疗的伴有严重角化皮肤病的赖特综合征。一名38岁男性于1985年12月因难治性皮疹和多关节痛被转诊至我院。他曾于1983年12月患尿道炎,随后出现高热、龟头炎、皮疹和多关节炎。当时使用抗生素、抗炎药和糖皮质激素治疗均无效。根据患者的临床症状及HLA - B27的存在,诊断为赖特综合征。他在我院门诊接受口服依曲替酯(芳香维甲酸)治疗,初始剂量为40mg/天,2周后增至75mg/天。该维持剂量持续两个月,关节疼痛、皮疹及实验室异常情况均有改善。依曲替酯剂量逐渐减少,4个月后约90%的皮肤损害消失时停药。除轻微口腔炎外,未观察到明显副作用。停用依曲替酯且未用药后,缓解持续约2年半。然而,1989年3月观察到有相同皮肤损害和关节痛复发的迹象。再次尝试口服依曲替酯治疗,效果相似但稍有延迟。